| Description: |
In vitro, SB273005 inhibits human osteoclast-mediated bone resorption with IC50 of 11 nM. In blood containing MDA-MB-231 cells, a combination of SB273005 and lamifiban inhibits tumor cell adhesion to vascular extracellular matrix (ECM). In rat models of bone resorption and osteoporosis, SB273005 (30 mg/kg, p.o.) inhibits the parathyroid hormone-stimulated calcemic response, and inhibits bone loss. In rat with adjuvant-induced arthritis, SB273005 (60 mg/kg, p.o.) significantly reduces the symptoms of adjuvant-induced arthritis. SB273005 (1000 mg/kg/day, p.o.) causes acute, transient necrosis of vascular smooth muscle cell (VSMC) in aorta and renal arteries of mice. In pregnant mice, SB273005 reverses the reduction of Th1 cell-produced IL-2 levels and the increase of Th2 cell-derived IL-10 levels. [5] For the detailed information of SB273005, the solubility of SB273005 in water, the solubility of SB273005 in DMSO, the solubility of SB273005 in PBS buffer, the animal experiment (test) of SB273005, the cell expriment (test) of SB273005, the in vivo, in vitro and clinical trial test of SB273005, the EC50, IC50,and affinity,of SB273005, For the detailed information of SB273005, the solubility of SB273005 in water, the solubility of SB273005 in DMSO, the solubility of SB273005 in PBS buffer, the animal experiment (test) of SB273005, the cell expriment (test) of SB273005, the in vivo, in vitro and clinical trial test of SB273005, the EC50, IC50,and affinity,of SB273005, Please contact DC Chemicals. |
